1. Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis
- Author
-
Anna Sonia Petronio, Cristina Giannini, Marco De Carlo, Maria Grazia Delle Donne, Fabio Guarracino, Giovanni Benedetti, and Francesco Verunelli
- Subjects
medicine.medical_specialty ,Ticlopidine ,Percutaneous ,medicine.medical_treatment ,Prosthesis ,Risk Factors ,medicine ,Humans ,High surgical risk ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Percutaneous aortic valve replacement ,Aspirin ,business.industry ,Calcinosis ,Aortic Valve Stenosis ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Clopidogrel ,Prosthesis Failure ,Surgery ,Treatment Outcome ,Echocardiography ,Aortic Valve ,Aortic valve stenosis ,cardiovascular system ,Female ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Echocardiography, Transesophageal ,Platelet Aggregation Inhibitors ,Follow-Up Studies - Abstract
Percutaneous aortic valve replacement is an emerging alternative for high surgical risk patients with native aortic valve stenosis. We describe for the first time a valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis.
- Published
- 2013
- Full Text
- View/download PDF